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Grade 2 and higher radiation pneumonitis (RP2) is a potentially fatal toxicity that limits efficacy of radiation
therapy (RT). We wished to identify a combined biomarker signature of circulating miRNAs and cytokines which,
along with radiobiological and clinical parameters, may better predict a targetable RP2 pathway. In a prospective
clinical trial of response-adapted RT for patients (n = 39) with locally advanced non-small cell lung cancer, we
analyzed patients’ plasma, collected pre- and during RT, for microRNAs (miRNAs) and cytokines using array and
multiplex enzyme linked immunosorbent assay (ELISA), respectively. Interactions between candidate bio
markers, radiobiological, and clinical parameters were analyzed using data-driven Bayesian network (DD-BN)
analysis. We identified alterations in specific miRNAs (miR-532, -99b and -495, let-7c, -451 and -139-3p)
correlating with lung toxicity. High levels of soluble tumor necrosis factor alpha receptor 1 (sTNFR1) were
detected in a majority of lung cancer patients. However, among RP patients, within 2 weeks of RT initiation, we
noted a trend of temporary decline in sTNFR1 (a physiological scavenger of TNFα) and ADAM17 (a shedding
protease that cleaves both membrane-bound TNFα and TNFR1) levels. Cytokine signature identified activation of
inflammatory pathway. Using DD-BN we combined miRNA and cytokine data along with generalized equivalent
uniform dose (gEUD) to identify pathways with better accuracy of predicting RP2 as compared to either miRNA
or cytokines alone. This signature suggests that activation of the TNFα-NFκB inflammatory pathway plays a key
role in RP which could be specifically ameliorated by etanercept rather than current therapy of non-specific
leukotoxic corticosteroids.

Introduction
Chemoradiation (ChemoRT) followed by the immune checkpoint
blocker (ICB) durvalumab has become the new standard of care for
patients with locally advanced NSCLC patients [1]. Unfortunately,
treatment of locally advanced NSCLC is complicated by the frequent
occurrence of symptomatic (grade 2 or higher) radiation pneumonitis

(RP) which may occur in up to 25% of patients [2–4]. Multiple recent
reports noted a rise in symptomatic Grade 2+ pneumonitis with adju
vant ICB [5–7]. In a nationwide cohort of more than 2,000 patients, we
found that grade 3+ pneumonitis was the most common toxicity in
locally advanced lung patients [8] and that it led to discontinuation of
potentially curative durvalumab in more than 10% of “real-world” pa
tients as compared to 3% enrolled on PACIFIC trial (which only scored
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grade 3 RP and included only patients who successfully completed
chemoRT without RP). High dose corticosteroids are given to symp
tomatic patients with Grade 2+RP, but this induces leukopenia which
may negatively impact ICB efficacy [9,10]. We have found on multi
variate analysis that the development of immune-related Adverse Events
(irAE) in locally advanced NSCLC patients significantly reduced overall
survival [8]. Therefore, there is an unmet clinical need to develop im
mune sparing RP treatment strategies.
Lung irradiation causes the release of inflammatory cytokines and
miRNAs that can promote early acute RP and late pulmonary fibrosis
(PF) [11,12]. Among various cytokines, early release of TNFα plays a
priming role in RP [13]. Thus, targeting of TNFα signaling is a possible
strategy to develop a lung radioprotector [14]. Our preclinical data
showed that inhibition of TNFα signaling by genetically deleting the
receptor 1 (TNFRSF1A-null mice) or via antisense oligonucleotide (ASO)
protects the lung from radiation toxicity [14]. We further extended our
observation using Tristetraprolin (TTP, Zfp36 in mice) knockout mice,
which have high basal levels of TNFα. TTP is a key negative regulator of
TNFα by causing its mRNA degradation. These mice develop RP symp
toms within a week post-irradiation [15]. In the TNFα-TNFR1 mediated
inflammatory signaling, TNFα converting enzyme (TACE), also known
as A disintegrin and metalloproteinase 17 (ADAM17), plays a key role by
cleaving membrane-bound TNFα (mTNFα) to release soluble TNFα. In
normal circumstances, cellular homeostasis is maintained by
ADAM17-mediated cleavage of the membrane-bound TNFR1 (mTNFR1)
to release its extracellular soluble form (sTNFR1), that can bind TNFα to
block inflammation [16]. However, ADAM17 has ~100-fold higher af
finity for the mTNFα compared to mTNFR1 [17]. ADAM17 is secreted by
various cell types including lung cancer cells, but following RT-mediated
tumor cell killing, the possibility exists for limiting levels of active
ADAM17, which along with differential affinity would lead to a decrease
in sTNFR1 yet will maintain higher levels of soluble TNFα to promote
inflammation. Prior to the current study, the involvements of ADAM17
in TNFα-TNFR1 mediated inflammation during RP have not been stud
ied in detail.
The involvements of multiple other cytokines, particularly IL-4, -8,
-12, -13, TGF-β1, MCP-1 (CCL-2), have been described in preclinical RP
models as well as patients showing pneumonitis [Ref. [18] and refer
ences therein]. In addition, studies reporting the roles of circulating
miRNA involved in RP have started to emerge. In one of the earlier
studies, Dinh et al. identified decreased expression of miR-29a-3p and
miR-150-5p following RT in NSCLC patients [19]. In addition, the
polymorphism of miR-125a, which lowers its expression, has been
linked to RP [20,21].
RP is a complex disease likely to involve the interaction of various
lung cell types, resident and infiltrating immune cells and tumor cells.
All these cells release multiple cytokines, chemokines, miRNAs and
other factors, whose expressions are further altered following RT.
However numerous investigations of biological markers, predominantly
using either cytokines or miRNAs, have not produced a consensus on the
inflammatory pathway(s) involved. Data-driven Bayesian network (DDBN) computer algorithms can handle multiple parameters at once, and
we have previously utilized such an approach to successfully predict
local tumor control in NSCLC patients for response-adopted radio
therapy [22]. In the current study have combined several approaches to
analyze biological variables (circulatory cytokines and miRNAs
collected prior to and multiple times during RT) and examine their re
lationships to mean lung dose (MLD) and clinical parameters to identify
a biomarker signature for NSCLC patients who may be at higher risk of
developing RP2.

driven adaptive radiation therapy for patients with locally advanced
NSCLC (NCT02492867). This study was designed to apply functional
imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDGPET) ("a PET scan") and Ventilation/Perfusion Single Photon Emission
Computerized Tomography (V/Q SPECT) ("a perfusion scan") before
treatment and then again during treatment to study therapeutic efficacy
and lung function. Blood samples were collected for biomarker studies
pre-treatment, during-treatment (at day 1, 2, 5, week 2, 3, 4, 5 and 6
during chemoradiation), and in follow-up after chemoradiation (1month post-RT, and then every 3-months post-RT for the first year).
Blood samples were immediately processed in the laboratory after
collection, as described below. Patient were followed clinically after
concurrent chemoradiation at 1 month and 3 months post-treatment,
and then every 3 months for the first year, then every 6 months until
year 3, then annually through year 5. Toxicity, including pneumonitis,
was recorded and graded according to Common Terminology Criteria
for Adverse Events (CTCAE v4.0).
Radiation therapy
Patients received radiation treatment 5 days per week, in once daily
fractions, for 30 treatments with dose per fraction individually adapted
over the final 9 treatments based on individual FDG-PET response and
V/Q SPECT response during treatment [23]. The intent of delivering
response-based treatment was to intensify the dose to active tumor while
limiting normal tissue toxicity to an estimated RP2 rate of 15%, and
grade 2 or greater esophagitis rate of 30% [24]. Patients also received
concurrent chemotherapy with carboplatin and paclitaxel. Following
completion of concurrent chemoradiation, patients received consolida
tion chemotherapy (carboplatin and paclitaxel) or ICB (durvalumab) at
the discretion of the medical oncologist.
Specimen collection
All specimens were prospectively collected under an institutional
review board-approved protocol (HUM00098202) after receiving
informed patient consent. Plasma samples were processed from blood
collected in EDTA tubes (Fisher, Cat No. 02-657-32). Briefly, within one
hour of blood draw, the blood was centrifuged at 3400 × g for 10 min at
room temperature. The supernatant was then centrifuged at 1940 × g for
10 min at room temperature with no brake during the deceleration. The
resulting supernatant was then aliquoted and frozen at − 80 ◦ C.
RNA isolation from patient plasma
Patient plasma (same time frame collected from different patients)
was thawed at 37 ◦ C for a maximum of 3 min, with a batch limit of 12
samples handled at once. RNA was extracted utilizing the miRNeasy
Micro Kit (Cat#217004, Qiagen) according to manufacturer’s instruc
tion. In brief, 200 μl of plasma was mixed by vortexing with 1 mL of
Qiazol, incubated at room temperature for 5 min, then mixed with 200
μl of chloroform, and centrifuged. The upper aqueous phase was mixed
with 1.5 volumes of ethanol and purified using the miRNeasy mini
column. Isolated miRNAs were stored at − 80 ◦ C until analysis.
Quantification miRNA using OpenArray
Isolated RNA was first reverse transcribed and pre-amplified using
separate A and B primer pools, following the Life Technologies Open
Array protocol (4461306 Rev. C) with modifications for low input (Life
Tech Application Note). TaqMan OpenArray Human MicroRNA,
QuantStudio 12K Flex Panels (part no. 4470187) and the necessary re
agents indicated in the OpenArray protocol were provided by Life
Technologies. The Accufill robot was used to load panels in accord with
standard protocols (part no. 4456986 Rev. A), and the sample was
thermally cycled immediately in the QuantStudio 12K Flex Real-Time

Materials and methods
Clinical trial design
Samples were collected from a pilot prospective study of response2
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PCR instrument. Raw data (*.eds files) were exported in *.txt files for
analysis with Microsoft Excel and other statistical R software packages.

were removed, as they would not be effective at predicting RP. Patients
(n = 26) were divided into pneumonitis and non-pneumonitis groups,
and the CT values of the remaining miRNAs were compared across
groups using t-tests, to assess the individual significance of each miRNA.
We used false discovery rate adjusted p-values to account for multiple
hypothesis testing. We also sought to predict RP2 by considering mul
tiple miRNAs simultaneously, which was performed through multivar
iable linear regression. Models were selected via a forward selection
process using the Akaike Information Criterion (AIC), and variables with
high variance inflation factors were removed to address multi
collinearity issues. This process was applied three times to create models
using pre-treatment miRNA values, during treatment miRNA values, and
delta (pre-treatment minus during treatment) values as predictors for
RP.

Multiplex cytokine analysis
Levels of selected plasma cytokines from samples collected at pre-, 2
and 4 weeks (represent the most complete dataset) during-treatment
time points were quantified using Procartaplex 15-plex customized
ELISA kit (Cat# PPX-15, Life Technologies, Grand Island, NY) according
to manufacturer’s instruction. In brief, ProcartaPlex™ immunoassays
use magnetic microsphere technology to detect multiple protein targets,
here cytokines and chemokines. In the current study, based on our prior
findings and literature summary, we selected 15 target inflammatory
cytokines [sTNFR1 (for TNF-α), IFN-γ, IL-1α, IL-1β, IL-4, -6, -8, -15, -17α,
-23, IP-10 (CXCL-10), MCP-1 (CCL2), PDGF-bb, CD40L, GM-CSF] to
develop a customized assay panel. Prior to running the assay, plasma
samples were thawed on ice and then centrifuged at 10,000 × g. The
supernatants were assayed in duplicate per manufacturer protocol and
analyzed on a Luminex microplate reader.

Cytokine analysis
For cytokines, we applied univariate linear, multivariate linear
regression and log transformation analyzes. Based on univariate anal
ysis, none of the cytokines showed statistical significance. Also, due to
small sample size (n = 39) with a larger number of variables (15 cova
riates), Lasso was impossible to perform. For stepwise regression for
feature selection based on AIC (Akaike Information Criterion), we first
developed a model (Model 1) by fitting linear regression model with all
covariates. We then conducted stepwise regression for Model 1 to get
Model 2, followed by calculation of variance inflated factor (VIF) of
Model 2 and deleted the variable with highest VIF. We repeated the
above steps until all the VIFs were less than 10.

sTNFR1 ELISA
Plasma samples were assayed for sTNFR1 using the Quantikine
ELISA kit (Cat#DRT100, R&D systems, Minneapolis, MN) according to
the manufacturer’s protocol. Briefly, each plasma sample was diluted
1:10 in the provided diluent and assayed in duplicate. The samples were
incubated, on plate, with assay diluent for 2 h at room temperature and
then washed 3 times with the supplied wash buffer. Human TNFR1
conjugate was added to each well followed by another 2 h of incubation.
Following an additional 3 washes, the substrate and stop solutions were
added, and the plate was read on a plate reader per manufacturer pro
tocol. Cytokine concentrations were calculated against a standard curve
utilizing the TNFR1 protein standard supplied with the ELISA.

Data-driven Bayesian network (DD-BN) analysis
To unravel radiobiological interactions of cytokines and miRNA
biomarkers along with the TNFα-NFκB signaling pathway in RP2 pre
diction, our previously developed graphical DD-BN approaches were
employed to identify the most robust radiobiological variables related to
RP2 prediction [22,26]. A BN is a probabilistic directed acyclic graphical
model that uses Bayesian inference to estimate conditional dependence
of involved variables. Our DD-BN approach further allows exploring
these variables’ potential causal-effect relationships in terms of response
to radiation treatment through robust BN structure learning and
parameter estimation before and during radiotherapy. As radiation
induced lung toxicity is influenced by dose per fraction [27], for DD-BN
modeling we decided to use gEUD [22,26] instead of mean lung dose
(MLD), a more widely used parameter directly obtained from radiation
therapy planning. Nested cross-validation and area under receiver
operating characteristic (ROC) were used to evaluate the prediction
performance of these DD-BN models. The prediction 95% confidence
intervals were calculated using statistical resampling with 2000 strati
fied bootstrap replicates.

ADAM17 ELISA
Total amounts of ADAM17 present in patients’ plasma were quan
tified using an ELISA kit (Cat # EHADAM17, Thermo Fisher) according
to manufacturer’s instructions. In brief, 50 μl of plasma from each pa
tient was incubated with Anti-Human TACE Strip Plate for 2.5 h in
triplicate. The samples were processed according to the protocol,
maintaining the incubation time, and washing steps. Following colori
metric assay, absorbance was measured at 450 and 550 nm, and the final
values was calculated by subtracting absorbance at 550 nm from 450 nm
to correct for optical imperfections in the microplate.
Immunoblotting of active ADAM17 from patient plasma
Thawed plasma samples were first diluted 50-fold with ice-cold PBS,
and the protein concentrations were quantified using the Bradford
method according to manufacturer’s protocol (Cat. B6916, Sigma). 15
ug of protein from plasma samples was loaded in a 4–12% bis-tris gel
(Invitrogen, Cat# NP0321) and immunoblotted as standardized and
described earlier [15]. For the detection of active ADAM17, we pur
chased an antibody (Cat# ABT94, Sigma) at a dilution of 1: 50,000.

Results
Patient characteristics
This study included 39 locally advanced non-small cell lung cancer
patients, and the characteristics (demographic clinical and treatment
data) are shown in Table 1. In this cohort, we recorded 8 cases (~20%)
of grade 2 and above radiation pneumonitis cases.

Statistical analysis

Alteration of circulating cytokines that predict RP

miRNA analysis
To obtain the most reliable miRNA values and their associated
changes, we performed three sequential steps: quality assessment, nonspecific filtering and differential expression analysis as described in a
recent publication [25]. In brief, a miRNA 1:4 dilution experiment was
performed to determine which miRNAs had cycle threshold (Ct) value
measurements consistent with the expected changes from the dilution.
Of these reliable miRNAs, those that were not variant across samples

Mean lung dose (MLD) is a known confounder to consider while
analyzing the role of cytokines and miRNA on RP [28]. To understand
the proportion of variation explained by MLD, a linear regression model
showed that in our dataset MLD alone was not sufficient to predict
toxicity (p-value = 0.125 > 0.05). Therefore, we decided to include MLD
when fitting the subsequent multivariate regression model using
3
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Table 1
Demographic, clinical, and treatment data.
Parameters
Age (years)
Median (range)
Sex, n (%)
Male
Female
Zubrod Performance Status, n (%)
0
1
2
Smoking Status, n (%)
Never
Former
Current
Stage Group, n (%)
IIA
IIIA
IIIB
IIIB-C
IIIIA
Concurrent Chemotherapy, n (%)
Yes
Radiation Dose, Gy
Physical Dose
Median (range)
EQD2
Median (range)
BED (Gy)
Median (range)
Mean Lung Dose (Gy)
Median (range)
Highest Pneumonitis Grade n (%)
0
1
2
3

Table 2
Multivariate linear regression model showing identified cytokine signature
those correlate with highest pneumonitis (RP) grade at the indicated time points.

All Patients (n = 39)

A. Fitting model between pretreatment cytokine values and highest RP grade
(adjusted R2 = 0.222)
Cytokines
Estimate
Std. Error
Pr (>ItI)

66 (54, 81)
26 (66.7%)
13 (33.3%)

IL-4
0.645
0.237
0.011
IP-10
0.333
0.203
0.110
IL-6
0.422
0.187
0.031
IFNγ
− 1.354
0.247
0.00001
MCP1
− 0.399
0.120
0.002
IL-23
− 0.483
0.167
0.007
PDGF-bb
0.685
0.252
0.011
MLD
0.066
0.026
0.019
B. Fitting model between Wk2 cytokine values and highest RP grade (adjusted R2 =
0.183)
Cytokines
Estimate
Std. Error
Pr (>ItI)
IL-4
0.430
0.275
0.130
IL-6
− 0.885
0.285
0.005
IL-1α
0.493
0.216
0.031
MLD
0.094
0.037
0.018
C. Fitting model between Wk4 cytokine values and highest RP grade (adjusted R2 =
0.219)
Cytokines
Estimate
Std. Error
Pr (>ItI)
IP-10
0.435
0.123
0.001
IL-8
− 0.968
0.222
0.0001
IL-23
0.694
0.209
0.002
MLD
0.086
0.030
0.008
D. Fitting model between Wk2 minus baseline cytokine values and highest RP grade
(adjusted R2=0.183)
Cytokines
Estimate
Std. Error
Pr (>ItI)
IL-8
0.698
0.312
0.035
IL-23
− 0.440
0.263
0.108
IL-15
0.675
0.406
0.110
CD40L
− 0.707
0.266
0.014
PDGF-bb
− 0.573
0.307
0.075
MLD
0.088
0.038
0.032
E. Fitting model between Wk4 minus baseline cytokine values and highest RP grade
2
(adjusted R =0.199)
Cytokines
Estimate
Std. Error
Pr (>ItI)
IP-10
− 0.444
0.124
0.001
MCP-1
0.262
0.121
0.038
IL-1α
− 0.328
0.118
0.009
MLD
0.086
0.030
0.008
F. Fitting model between Wk4 minus Wk2 cytokine values and highest RP grade
2
(adjusted R = 0.3)
Cytokines
Estimate
Std. Error
Pr (>ItI)
IL-1b
0.919
0.214
0.0005
IP-10
− 0.476
0.255
0.079
sTNFR1
− 0.581
0.197
0.009
IFNγ
0.609
0.309
0.065
GM-CSF
− 0.561
0.246
0.036
IL-1α
− 0.195
0.153
0.220
IL-23
− 0.575
0.208
0.013
MLD
0.118
0.030
0.001

8 (20.5%)
29 (74.4%)
2 (5.1%)
2 (5.1%)
24 (61.5%)
13 (33.4%)
1 (2.6%)
18 (46.1%)
18 (46.1%)
1 (2.6%)
1 (2.6%)
39 (100%)
67.8 (59.97, 80.40)
69.29 (60.20, 86.30)
83.15 (72.24, 103.56)
15.131 (5.745, 21.1)
24 (61.6)
7 (17.9)
7 (17.9)
1 (2.6)

cytokines as a biomarker. We performed a customized multiplex ELISA
screening for 15 selected inflammatory cytokines (as described in Ma
terials and Methods) in 39 patients’ plasma samples (with 8 reported
toxicities). Table 2 shows the association between the lung toxicity and
the cytokines via multivariate linear regression model. The cytokine
levels used for analysis were either prior to radiation therapy (base line),
or after 2- or 4-weeks during treatment. The model accuracy is shown by
the coefficient of determination as adjusted R2. For the base line cyto
kine values, the adjusted R2=0.222 after leave-one-out cross-validation
(Table 2A), which included 7 cytokines (IL-4, IP-10, IL-6, IFN-γ, MCP-1,
IL-23, and PDGF-bb). Cytokine expression differences noted at week 2
(IL-4, -6, -1α with R2 value of 0.183) and week 4 (IP-10, IL-8 and -23
with R2 value of 0.219) (Table 2B,C). The cytokine signature obtained
based on the difference between week 2 and week 4 from the baseline
and between week 4 minus week 2 are included in Table 2D–F,
respectively.

patients. While analyzing plasma samples collected from matched pa
tients at multiple time points (day 1, 2, 5, week 2, 3, 4, 5 and 6) during
RT, we noted RP symptoms in patients who showed lowering of sTNFR1
within 2–4 weeks of RT (Fig. 1B).

High basal level of sTNFR1 and its transient drop correlate with RP
After identifying inflammatory cytokine signature as potentially
predictive biomarkers of radiation-induced lung toxicity, we wished to
assess the involvement of TNFα. We previously identified the impor
tance of TNFα signaling in RP in a mouse model [15], and here our
cytokine signature from patient samples identified a drop in sTNFR1 as
one of the predictors of RP. Recognizing, as described in the introduc
tion, that sTNFα, which is very labile, and sTNFR1 are in a dynamic
balance it was of interest to quantify sTNFR1 [29] both at the base line
and at multiple time points during RT. As shown in Fig. 1A, prior to
radiation therapy, the average sTNFR1 level was 1334.8 ± 585.6
pg/mL, which is significantly higher than previously reported values
found among healthy individuals (~200 pg/mL) [30], suggesting the
existence of basal inflammation in the majority of our lung cancer

Change in ADAM17 levels in RP and non-RP patients
Active ADAM17 is involved in shedding of both the membrane
bound TNFα and TNFR1, but with differential affinity; ADAM17 has
100-fold higher affinity for membrane-bound TNFα as compared to
TNFR1 [17]. Hence, we compared the levels of ADAM17 in non-RP and
RP patients with the hypothesis that in an ADAM17 low environment,
sTNFR1 (anti-inflammatory) shedding may be compromised, while
circulating TNFα (inflammatory) may remain high to promote inflam
mation noted among RP patients (Supplementary Fig. S5). Ionizing ra
diation is reported to activate ADAM17 [31], however, we identified
two patterns for ELISA measuring ADAM17 protein levels in the plasma
of NSCLC patients undergoing chemoradiation as part of this
4
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Fig. 1. High basal level of TNFα and a transient
decrease in sTNFR-1 levels correlate with RP.
(A) Soluble TNFR1 (sTNFR1) levels present in
the patients’ plasma (n = 38) prior to RT was
calculated using sandwich ELISA. The red
(1334.8 ± 585.6 pg/ml) dotted line indicates
average levels of sTNFR1 in lung cancer pa
tients. The black dotted line indicates sTNFR1
levels among healthy individuals as reported in
a prior study [30]. (B) sTNFR1 levels were
calculated in patients’ plasma collected
pre-treatment (baseline), and after different
time points following initiation of RT (day 2, 5,
week 2, 4, and 6), and after 1, 3 and 6 months
of 5-FU treatment. Log ratio relative to the
baseline sTNFR1 [logΔ(sTNFR1)] was plotted
against day post first fraction of RT received. A
logistic model of predicting the occurrence of
RP2 toxicity was fit based upon logΔTNFR1
(14), i.e. the estimated log-ratio of sTNFR1
comparing 14 days after the first fraction to
pre-treatment. The assumption of these models
is that all toxicities occurred after 2 weeks’
time. The blue and red thick lines give the
group-wise (no RP2 vs RP2+, respectively)
smoothed average with corresponding confi
dence band. The vertical line marks day 14,
against which the logistic models were fit.

observational clinical trial. The first showed a subset of patients with
initially very low levels of ADAM17, where <10 pg/mL average ELISA
units were chosen as the cleanest visual threshold. These samples rep
resented 20.5% of patients (8/39) with similar proportions in RP (3/8,
37.5%) and no-RP (5/30,16.7%) patient groups (Fisher Exact P = 0.15;
Fig. 2A). In these samples ADAM17 levels tended to remain low
following irradiation, with 4 samples in particular (50%) remaining
below the 10 pg/mL threshold for both WK2 and WK4 measures, as
opposed to 1/5 (20%) and 3/25 (12%) in RP and non-RP high
er-expressing groups, respectively (Fig. 2B,C). Since the ELISA we per
formed cannot distinguish active and total protein forms, the ultra-low
levels can be taken as low ADAM17 activity, while higher levels may not
always correlate with higher activity as multiple factors are known to
influence ADAM17 catalytic activity [32]. Kruskal-Wallis non-para
metric comparisons (Dunn corrected for three sample groups) for WK2
and WK4 time points showed no significant differences in total ADAM17
levels between RP and non-RP groups (Fig. 2A–C).
To focus specifically on functional ADAM17 levels, we assessed
plasma levels for active ADAM17 using immunoblotting for 24 of the 39
total samples and using fold change (FC) to compare band intensities for
WK2 and WK4 to those of baseline (pre-treatment) for each available
sample (Fig. 2D,E). When FC was considered for the three sample groups
(low ADAM17 ELISA; n = 6; as well as RP and non-RP with higher ELISA
levels; n = 7 and 17, respectively), there was a trend towards lower FC
levels for RP vs non-RP samples across both weeks, with a Kruskal-Wallis
P = 0.025 at WK2 (Fig. 2F) and P = 0.23 at WK4 (Fig. 2G). Interestingly
FC levels for both low ELISA and non-RP sample groups showed simi
larly high FC values, averaging over 1 (generally increased) for both
WK2 and 4 (Fig. 2F,G), recapitulating prior data [31]. Collectively, the

above data suggest that a subset of samples have consistently low and
less amount of active ADAM17, while a subset with higher total
ADAM17 levels with limited catalytic activity in the early stages of ra
diation exposure.
Alteration of circulating miRNA that predict RP
To strengthen biomarker signature, besides cytokines we also
quantified plasma circulating miRNA. To determine the assay sensitivity
and to identify most reliable miRNAs, we initiated our studies by
quantifying equimolar and ratiometric pools of chemically synthesized
RNA oligonucleotides as described previously [25]. The raw data
quantifying miRNA consisted of CT values for 818 miRNAs from 26 out
of total 39 patients (2 RNA samples failed quality control and 11 others
were collected post analysis) taken prior to RT (baseline) and at WK4
during RT. The list of 70 reliable miRNA (Supplementary Table 1) and a
boxplot of these un-normalized CT values is shown in Supplementary
Fig. S1. In the dilution experiment, we analyzed RNA isolated from 3
patients and used two replicates of 1:4 dilutions. For a reliable miRNA,
we expected the difference in CT value from the quarter dilution sample
to the undiluted sample to be 2. We accepted a miRNA as reliable if, for
each run of the experiments (3 patients, 2 replicates each), the difference
in CT value for the that miRNA was between 1 and 3. This narrowed
down the initial pool of 818 miRNAs to 70. A boxplot consisting of the
70 reliable miRNAs is shown in the Supplementary Fig. S2. For each
miRNA, we calculated the variance of the delta (pre-treatment minus
during treatment) values across all the patients and removed the miR
NAs in the bottom 10% of delta value variances. This filtering reduced
the number of variables to 63 miRNAs, of which 9 were U6 miRNAs;
5
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Fig. 2. RP patients showed lowered active ADAM17 levels following RT. Total ADAM17 concentration (pg/mL) measures for 38 NSCLC patients, represented as a
log2 scale for (A) before treatment (pre-treat), (B) at week2 (WK2) and (C) at week 4 (WK4) of radiation treatment, as described in Methods. Each datapoint
represents the mean of 3 independent ELISA reactions on the same patient plasma sample. Samples were divided into 3 groups based on a) low initial levels (<10 pg/
ml) indicated by triangular symbols vs those with higher levels (>10UI/ml) circular symbols, as well as to distinguish RP2 (red symbols) from those of patients that
did not develop RP (non-RP; blue symbols). The only significant 2 group post-hoc comparisons are shown, based on an Kruskal-Wallis non-parametric tests at WK2
and WK4 timepoints, with Dunn adjustments for multiple testing. In WK4, the comparison between samples with low initial concentration, and the non-RP sample
group yielded P = 0.0097. (D) Representative immunoblots of patients’ plasma collected pre-treatment, 2 and 4 weeks during treatment showing active ADAM17
levels among non-pneumonitic and pneumonitic patients. For normalization, equal amounts of protein (as quantified using Bradford method) were loaded. (E) Band
intensities were quantified using ImageJ considering pre-treatment active ADAM17 level as ‘1’. Representative immunoblotting and quantification were performed
for the RP (n = 6) and non-RP (n = 18) samples showing changes in active ADAM17 levels at week 2 and week 4 during RT. Welch’s t-test was performed to calculate
statistical significance. Analyzes of (F) WK2 and (G) WK4 fold changes (FC) relative to baseline (pre-treat) band intensities, considering 3 groups; very low baseline
pre-pro-ADAM17 levels vs those with higher baselines that either did or did not develop RP. Data indicate a difference whereby RP samples with moderate to high
baseline values tend to show reduced levels at WK2 (P = 0.048 vs low group and P = 0.025 vs non-RP). WK4 shows a similar, not nonsignificant trend. Meanwhile
both non-RP, and samples with initially low pre-pro-ADAM17 levels show a similar propensity for upward trending values in WK2 and WK4. P values provided by
Kruskal-Wallis tests with Dunn adjustment for multiple 2-group comparisons.

thus, we had 54 miRNAs to analyze.
For each of the 26 patients, we had an outcome of highest pneu
monitis grade, denoted as 0, 1, 2, and 3, with 3 being the most severe
toxicity. To create pneumonitis and non-pneumonitis groups, patients
with the highest grade of 0 and 1 formed the non-pneumonitis group,
while 2 and 3 formed the pneumonitis group. The histogram of the pvalues of the delta value t-test showed potential signs of significance

(Supplementary Fig. S3A). However, after performing false discovery
rate calculations (q-value), all the miRNAs failed to be significant
(Supplementary Fig. S3B). This suggested that the differences in indi
vidual miRNA CT values between the pneumonitis and the nonpneumonitis groups were not significant.
We then created models involving linear regression and stepwise
feature selection with highest pneumonitis grade as the outcome, and
6
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the 54 miRNAs as predictors. For the forward selection approach, we
used the Akaike Information Criterion (AIC) to select miRNAs to predict
pneumonitis. For the pre-treatment miRNA value model, we obtained 5
significant miRNAs (miR-532, -451, -99b, -139-3p, and Let-7c) with an
adjusted R2 of 0.6385 (Table 3A). For the delta value model (WK4 minus
pre-treatment), we obtained one significant miRNA (miR-495) with an
adjusted R2 of 0.3386 (Table 3B). Since the predictors are the CT values,
and CT values are inversely proportional to the amount of miRNA, a
positive coefficient represented a negative association between the
miRNA and toxicity, and vice versa. From the above analysis we iden
tified three miRNAs (miR-532, -495, -99b) positively correlated with
RP2, whereas the remaining three (miR-139-3p, -451, and let-7c) were
negatively correlated. Interestingly, reported studies on these afore
mentioned miRNAs identified them as regulators of NFκB [33–38], a key
mediator of multiple inflammatory signaling processes, including
radiation-induced normal tissue toxicity [39].

a temporal (2-4 weeks during RT) reduction of anti-inflammatory
sTNFR1 in RP2 patients, suggestive of a persistent inflammatory state.
Using DD-BN analysis, we combined biological, radiobiological, and
clinical data, which highlight the interactions between these variables as
discussed below.
A key finding of our work is that it required a combined assessment
of miRNAs, cytokines along with MLD to best predict radiation induced
lung inflammation indicating crosstalk between multiple biomarkers.
We previously reported that lung irradiation induces early release of
TNFα, and inhibition of TNFR1-mediated inflammatory signaling can
radioprotect mouse lung [14]. Conversely, Tristetraprolin (TTP, Zfp36 in
mice) knockout mice with high basal levels of TNFα were prone to RP
[14,15,40]. Such preclinical data allowed us to predict conservation of
the TNFα-TNFR1 pathway in clinical settings. Analysis of patients’
plasma using a multiplex cytokine array (Table 2) and conventional
sandwich ELISA (Fig. 1), showed that transient loss of sTNFR1 is one of
the contributing factors promoting RP. Besides activation of TNFα
signaling, involvements of IL-1α and IL-6 have been reported in inde
pendent clinical studies [41,42], which is consistent with our findings.
In another study with NSCLC patients during and after radiotherapy,
changes in the levels of IP-10, MCP-1 and IL-6 were found to be corre
lated with MLD [43], similar trend was noted in our study. However, to
better predict patients prone to develop RP, multiple biomarker analyzes
may be required where our approach of using DD-BN analysis will be
critical.
A possible involvement of TNFα-NFκB signaling in RP became
evident while analyzing miRNA data. From unbiased screening of the
total 818 miRNAs, we identified six [6] (miR-532, -99b and -495, let-7c,
miR139-3p and miR-451), which were correlated with RP incidence.
Interestingly, these miRNAs were previously reported to regulate NFκB
signaling, either as activators or inhibitors. Among activators, miR-99b
has been reported to promote NFκB-mediated inflammation via acti
vating expression of IL-1β, -6 and -12 [35]. Similarly, miR-495 is known
to be involved in inflammatory diseases, particularly Crohn’s disease,
where it regulates the expression of the nucleotide binding oligomeri
zation domain containing protein 2 (NOD2), a key inducer of multiple
cytokines including IL-6, -8 and TNFα (34). For expression of these in
flammatory cytokines NOD2 is an important activator of NFκB signaling
[44]. Although the direct role of miR-532 is not known, its connection
with NFκB signaling results via regulation of KIFC1 expression to impact
gankyrin/AKT signaling [45] and thus can indirectly impact NFκB; at
the same time, the promoter of miR-532 has an NFκB1 binding site for
direct regulatory feedback [33]. This miRNA is also aberrantly
expressed in patients with inflammatory bowel disease [46]. In contrast,
miR-451, -139-3p and let-7c are involved in NFκB regulation by nega
tively impacting transcription activation. For example, miR-451 directly
suppresses IKKβ expression, the critical kinase that inactivates the in
hibitor of NFκB signaling, IκB, via phosphorylation to promote protea
somal degradation [47]. This miRNA also suppresses TLR-4-mediated
expression of inflammatory cytokines including IL-6, -1β and TNFα.
Downregulation of this miRNA is also reported in nonalcoholic steato
hepatitis [48]. Similarly, miR-139 is known to inhibit NFκB-mediated
expression of IL-6, 1β and TNFα; thus, its targeted deletion promoted
intestinal inflammation and colorectal cancer in a mouse model [36].
Furthermore, let-7c expression is reported to be lower in chronic
obstructive pulmonary disease (COPD) patients [49], and its
anti-inflammatory role in LPS-induced inflammation is mediated via
suppression of STAT3 expression, a known collaborator of NFκB [50].
Taken together, the current literature supports our miRNA and cytokine
data, which identified a signature in lung cancer patients undergoing
thoracic radiation that resulted in the activation of TNFα-NFκB signaling
to cause RP.
One of the major strengths of this study is the use of DD-BN
modeling, which combined biological data (miRNAs and cytokines)
with radiobiological parameters, such as lung generalized equivalent
uniform dose (gEUD) [51]. As shown in Fig. 3, such an approach

A data-driven Bayesian network (DD-BN) approach to predict RP
We have previously developed a statistical method based on
resampling and information theory to guide robust development of BN
structure learning, where we integrated radiobiological variables in a
statistical resampling framework using bootstrap generated samples of
the data to represent their interaction graphically and allow further
inferences [22,26]. Utilizing the candidate variables from the statistical
analyzes, we generated stable BN structures using either miRNA, cyto
kines or both and combined them with radiobiological and clinical pa
rameters to best represent RP2 prediction, as shown in Fig. 3A–F and
Supplementary Fig. S4. In these BNs, arcs with green or red color
represent positive or negative association between any two variables in
the graph, while arcs with gray color indicate a mixture of positive and
negative association depending on the expression state of the involved
variables. The area under the ROC curves (AUCs) show that the per
formance of these BNs for RP2 prediction improved significantly when
all parameters were combined achieving an AUC of 0.87 (95%
0.75–0.97) on cross-validation testing.
Discussion
In this study, we have adopted an approach using data-driven
Bayesian Networks to understand the multiple interactions of miRNA
array and multiplex cytokines analysis, along with radiobiological (such
as MLD and gEUD) and clinical data to predict RP2. We identified spe
cific miRNAs (miR-532, -451, -99b, -139-3p, -495 and let-7c) and found
a signature using the WK4 minus WK2 difference which included 7 cy
tokines (IL-1β, IP-10, IL-23, sTNFR1, IFN-γ, GM-CSF, and IL-1α)
(Fig. 2B). This signature included either regulators (TNFα and IL-1α) or
targets of NFκB, a key downstream mediator of TNFα-driven inflam
mation [39]. We further identified higher basal levels of sTNFR1 in
majority of our lung cancer patients, however, surprisingly we observed
Table 3
Linear regression and stepwise selection with highest Pneumonitis grade iden
tified selected miRNAs pre-treatment (in A) and Wk4 during treatment (in B)
signature using Akaike Information Criterion (AIC).
A. Fitting model between pre-treatment miRNA values and highest RP grade (R2 =
0.6385)
miRNA
Estimate
Std. Error
Pr(>ItI)
miR-532
− 0.133
0.040
0.003
miR-451
0.316
0.075
0.0004
miR-99b
− 0.405
0.083
0.00009
Let-7c
0.222
0.059
0.001
miR-139-3p
0.099
0.055
0,08
B. Fitting model between pre-treatment miRNA values and highest RP grade (R2 =
0.3386)
miRNA
Estimate
Std. Error
Pr(>ItI)
miR-495
− 0.377
0.086
0.0002

7

T. Hinton et al.

Translational Oncology 21 (2022) 101428

Fig. 3. Pre- and during-treatment DD-BN for improved pre
diction of RP2. (A–C) Left panels represent pre-treatment BN
models using cytokines (in A), miRNAs (in B) and both (in C)
along with dosimetry parameter (lung_gEUD). Right panels
show corresponding ROC curves of pre-treatment DD-BN based
on internal cross-validation. (D-F) Left panels represent 4
weeks during-treatment BN models as above using cytokines,
miRNAs and both respectively and right panels show respec
tive ROC curves similarly analyzed and validated as above.

identified specific cytokines and miRNAs that showed either positive,
negative or mixed correlation and strengthened our RP2 prediction
ability both at the pre-treatment and during treatment (WK4) time
points as evidenced by the improvement of AUC values. Such data
further identified that besides increasing lung dose and loss of sTNFR1,
increases in IL-4 and MCP-1, at WK4 of treatment, positively correlated

with subsequent RP2 occurrence. A previous study using a rat model for
RP showed increase in IL-4 following a single dose of 20 Gy thoracic
irradiation [52]. Furthermore, a recent study identified association of
IL-4 genetic variation (single nucleotide polymorphism, SNP) with
prevalence of RP in lung cancer patients [53]. Similarly supportive,
MCP-1 (also called CCR2) is known to be altered in multiple
8
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inflammatory diseases, particularly following thoracic irradiation [54].
Thus, the DD-BN analysis helped us better understand the cross-talks
between different biological mediators, and their association with
lung dose to predict RP2. Such findings may have both predictive and
therapeutic value, as they suggest testing of anti-TNFα agents to prevent
RP2.
ICB therapy following RT has become the standard-of-care for lung
cancer patients, yet the use of high dose corticosteroids to treat RP may
be counterproductive due to their leukotoxicity and known negative
impacts on ICB efficacy. In a recent preclinical study, early blockade of
NFκB signaling using Thalidomide was shown to mitigate chronic
inflammation in radiation-induced urinary bladder dysfunction [55].
Our data suggest that an anti-TNF/NFκB agent may be an ideal
replacement. Thus, our signature biomarker will not only be useful in
identifying patients prone to RP, but it also suggests a new therapeutic
strategy to treat RP2. Such a strategy is further strengthened by recent
reports and our unpublished data that demonstrate prophylactic TNFα
blockade may potentiate ICB efficacy at least in preclinical models [56].
Although a recent retrospective study of patient outcomes from a Dutch
National Registry identified worse outcomes in patients whose ICB
toxicity was managed using anti-TNFα agent, particularly Infliximab
[57], in an associated commentary, certain shortfalls were also noted
with respect to data interpretation [58]. Thus, we are cautiously opti
mistic and believe the prevalence of data suggest that a detailed pre
clinical study using an anti-TNFα agent is warranted.
Another interesting finding from our study is the indication of a
transient reduction of sTNFR1 level between 2-4 weeks associated with
subsequent RT. sTNFR1 is the protease-cleaved extracellular domain of
TNFR1, which has the ability to bind and neutralize TNFα, thus acting as
an anti-inflammatory factor [59]. TNFα is initially synthesized as a
membrane-bound inactive form (mTNFα), which, following an insult
such as RT, undergoes processing by a metalloproteinase, called TNFα
converting enzyme (TACE, also cells ADAM17) [17]. ADAM17 is also
the protease for TNFR1; however, its enzymatic affinity is 100-fold
higher for TNFα as compared to TNFR1 [17]. Thus, in an ADAM-17
limited state, an inflammatory signal may persist due to increased
presence of soluble TNFα compared to sTNFR1. ADAM17 is initially
produced in its high molecular weight inactive pro-form, which can be
converted to an active-form [60]. Using immunoblotting, we noted
reduced levels of active ADAM17 in patients with RP2 between 2-4
weeks during RT, suggesting a time-sensitive limit in functional
ADAM17. It is interesting to note that we also found sTNFR1 shows a
similar drop in RP samples at WK2. These data provide preliminary
mechanistic insight (Supplementary Fig. S5), requiring more detailed
temporal sample collection and analysis.
We recognize that this study has some limitations. Most importantly,
the modest sample size (n = 39) and lack of validation cohort somewhat
restrict our inferences. Another potential weakness is overfitting of our
data, but we used statistical rigor to avoid this. Additionally, we
recognize that the direct quantification of TNFα poses a persistent
challenge to the field, which we have approached indirectly by
measuring sTNFR1 [29] and ADAM17.
In summary, we have utilized both miRNA and cytokines and using
DD-BN modeling combined biological data with radiobiological pa
rameters to identify signature biomarkers predictive of RP2, which
emphasized the role of TNFα-NFκB signaling in causing lung toxicity. As
both TNFα and NFκB are known mediators of various inflammatory
diseases, there are already multiple agents and FDA approved drugs
targeting these molecules, which can be repurposed for possible lung
radioprotection.
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